Spots Global Cancer Trial Database for central nervous system metastases
Every month we try and update this database with for central nervous system metastases cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer | NCT01706432 | Central Nervous... Invasive Ductal... Invasive Ductal... Invasive Lobula... Invasive Lobula... Liver Metastase... Lobular Breast ... Lung Metastases Male Breast Can... Medullary Ducta... Mucinous Ductal... Papillary Ducta... Recurrent Breas... Stage IV Breast... Tubular Ductal ... Tumors Metastat... | hyperfractionat... laboratory biom... stereotactic ra... | 18 Years - | University of Chicago | |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases | NCT01939483 | Central Nervous... Male Breast Can... Recurrent Breas... Stage IV Breast... | irinotecan hydr... laboratory biom... | 18 Years - | University of California, Irvine | |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | NCT03711422 | Non-small Cell ... Leptomeningeal ... Central Nervous... | Afatinib Afatinib | 21 Years - | National Cancer Centre, Singapore | |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | NCT03711422 | Non-small Cell ... Leptomeningeal ... Central Nervous... | Afatinib Afatinib | 21 Years - | National Cancer Centre, Singapore | |
| Focal Intraoperative Radiotherapy of Brain Metastases | NCT03789149 | Brain Metastase... Central Nervous... | Intraoperative ... | 18 Years - | AC Camargo Cancer Center | |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | NCT03653546 | Non-small Cell ... EGFR Gene Mutat... Brain Metastase... | AZD3759 Erlotinib Gefitinib | 18 Years - | Alpha Biopharma (Jiangsu) Co., Ltd. | |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | NCT03653546 | Non-small Cell ... EGFR Gene Mutat... Brain Metastase... | AZD3759 Erlotinib Gefitinib | 18 Years - | Alpha Biopharma (Jiangsu) Co., Ltd. | |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | NCT00098605 | Central Nervous... HER2-positive B... Male Breast Can... Recurrent Breas... Stage IV Breast... Tumors Metastat... | lapatinib ditos... laboratory biom... quality-of-life... questionnaire a... | 18 Years - | National Cancer Institute (NCI) | |
| Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | NCT03417544 | HER2-positive M... Central Nervous... | ATEZOLIZUMAB PERTUZUMAB TRASTUZUMAB | 18 Years - | Dana-Farber Cancer Institute | |
| Focal Intraoperative Radiotherapy of Brain Metastases | NCT03789149 | Brain Metastase... Central Nervous... | Intraoperative ... | 18 Years - | AC Camargo Cancer Center | |
| Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC | NCT03417544 | HER2-positive M... Central Nervous... | ATEZOLIZUMAB PERTUZUMAB TRASTUZUMAB | 18 Years - | Dana-Farber Cancer Institute | |
| Sunitinib in Treating Young Patients With Refractory Solid Tumors | NCT00387920 | Central Nervous... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Recurrent Child... Unspecified Chi... | sunitinib malat... pharmacological... dynamic contras... laboratory biom... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | NCT03711422 | Non-small Cell ... Leptomeningeal ... Central Nervous... | Afatinib Afatinib | 21 Years - | National Cancer Centre, Singapore | |
| Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer | NCT00992602 | Central Nervous... Leptomeningeal ... Recurrent Breas... Stage IV Breast... Tumors Metastat... | methotrexate liposomal cytar... quality-of-life... laboratory biom... | 18 Years - | University of Washington | |
| Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors | NCT01736800 | Central Nervous... Brain Metastase... | Topotecan Temozolomide | 18 Years - 79 Years | The Methodist Hospital Research Institute | |
| Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | NCT01783756 | Central Nervous... HER2-positive B... Male Breast Can... Recurrent Breas... Stage IV Breast... | lapatinib ditos... everolimus capecitabine laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Whole Brain Radiation Using IMRT for Patients With Brain Metastases | NCT02753790 | Neoplasm Metast... Central Nervous... | Intensity Modul... | 18 Years - | New Mexico Cancer Care Alliance | |
| Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | NCT00098605 | Central Nervous... HER2-positive B... Male Breast Can... Recurrent Breas... Stage IV Breast... Tumors Metastat... | lapatinib ditos... laboratory biom... quality-of-life... questionnaire a... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
